Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Basilea Pharmaceutica Ltd is a biotechnology company that focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections, and oncology. The company aims to develop drugs in order to target the medical challenge of resistance and non-response to current treatment options. Basilea generates its revenue from the European countries and the United States, while utilizing distribution agreements for the Middle East and North Africa regions. The company's research strategy integrates the areas of genomics, cell biology, medicinal chemistry, and pharmacology. The research teams work closely together with scientists in Basilea China in their search for novel molecules with distinct advantages over available therapies.
Basel, 4058, Switzerland